248 related articles for article (PubMed ID: 12431962)
1. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Kaiser U; Uebelacker I; Abel U; Birkmann J; Trümper L; Schmalenberg H; Karakas T; Metzner B; Hossfeld DK; Bischoff HG; Franke A; Reiser M; Müller P; Mantovani L; Grundeis M; Rothmann F; von Seydewitz CU; Mesters RM; Steinhauer EU; Krahl D; Schumacher K; Kneba M; Baudis M; Schmitz N; Pfab R; Köppler H; Parwaresch R; Pfreundschuh M; Havemann K
J Clin Oncol; 2002 Nov; 20(22):4413-9. PubMed ID: 12431962
[TBL] [Abstract][Full Text] [Related]
2. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
3. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
[TBL] [Abstract][Full Text] [Related]
4. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
5. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
6. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
7. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
[TBL] [Abstract][Full Text] [Related]
8. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
10. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Stewart DA; Bahlis N; Valentine K; Balogh A; Savoie L; Morris DG; Jones A; Brown C; Russell JA
Blood; 2006 Jun; 107(12):4623-7. PubMed ID: 16467197
[TBL] [Abstract][Full Text] [Related]
11. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.
Kluin-Nelemans HC; Zagonel V; Anastasopoulou A; Bron D; Roozendaal KJ; Noordijk EM; Musson H; Teodorovic I; Maes B; Carbone A; Carde P; Thomas J
J Natl Cancer Inst; 2001 Jan; 93(1):22-30. PubMed ID: 11136838
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity.
Fisher RI
J Clin Oncol; 2002 Nov; 20(22):4411-2. PubMed ID: 12431961
[No Abstract] [Full Text] [Related]
14. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Prayoonwiwat W; Numbenjapon T; Assawametha N; O'Charoen R; Swasdikul D
Clin Lymphoma; 2000 Dec; 1(3):219-25. PubMed ID: 11707834
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].
Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV
Vopr Onkol; 2003; 49(1):66-70. PubMed ID: 12715373
[TBL] [Abstract][Full Text] [Related]
16. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Schmitz N; Nickelsen M; Ziepert M; Haenel M; Borchmann P; Schmidt C; Viardot A; Bentz M; Peter N; Ehninger G; Doelken G; Ruebe C; Truemper L; Rosenwald A; Pfreundschuh M; Loeffler M; Glass B;
Lancet Oncol; 2012 Dec; 13(12):1250-9. PubMed ID: 23168367
[TBL] [Abstract][Full Text] [Related]
17. Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Linch DC; Yung L; Smith P; Maclennan K; Jack A; Hancock B; Cunningham D; Hoskin P; Qian W; Holte H; Boesen AM; Grigg A; Browett P; Trneny M
Br J Haematol; 2010 Apr; 149(2):237-43. PubMed ID: 20201949
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Jabbour E; Peslin N; Arnaud P; Ferme C; Carde P; Vantelon JM; Bocaccio C; Bourhis JH; Koscielny S; Ribrag V
Leuk Lymphoma; 2005 Jun; 46(6):861-7. PubMed ID: 16019530
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Pfreundschuh M; Zwick C; Zeynalova S; Dührsen U; Pflüger KH; Vrieling T; Mesters R; Mergenthaler HG; Einsele H; Bentz M; Lengfelder E; Trümper L; Rübe C; Schmitz N; Loeffler M;
Ann Oncol; 2008 Mar; 19(3):545-52. PubMed ID: 18065407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
